Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $36.0 in the last session, down -0.83% from day before closing price of $36.3. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 1.49 million shares were traded. RARE stock price reached its highest trading level at $36.48 during the session, while it also had its lowest trading level at $35.65.
Ratios:
We take a closer look at RARE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.74 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 94.23 whereas as Long-Term Debt/Eq ratio is at 85.75.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $65.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 10 ’25 when HOWARD HORN bought 3,081 shares for $36.38 per share.
Horn Howard sold 7,942 shares of RARE for $250,252 on Oct 13 ’25. The Chief Financial Officer now owns 98,227 shares after completing the transaction at $31.51 per share. On Sep 18 ’25, another insider, Huizenga Theodore Alan, who serves as the SVP, Chief Accounting Officer of the company, sold 64 shares for $29.17 each. As a result, the insider received 1,867 and left with 50,242 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3473192448 and an Enterprise Value of 3911828224. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.51 while its Price-to-Book (P/B) ratio in mrq is 378.39. Its current Enterprise Value per Revenue stands at 6.203 whereas that against EBITDA is -7.69.
Stock Price History:
The Beta on a monthly basis for RARE is 0.11, which has changed by -0.22584772 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $50.00, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is 8.50%, while the 200-Day Moving Average is calculated to be 6.48%.
Shares Statistics:
According to the various share statistics, RARE traded on average about 1.51M shares per day over the past 3-months and 1421200 shares per day over the past 10 days. A total of 96.27M shares are outstanding, with a floating share count of 89.76M. Insiders hold about 6.96% of the company’s shares, while institutions hold 99.09% stake in the company. Shares short for RARE as of 1764288000 were 8871538 with a Short Ratio of 5.88, compared to 1761868800 on 7144800. Therefore, it implies a Short% of Shares Outstanding of 8871538 and a Short% of Float of 9.520000000000001.
Earnings Estimates
A comprehensive evaluation of Ultragenyx Pharmaceutical Inc (RARE) is underway, with the input of 12.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.47, with high estimates of -$0.91 and low estimates of -$1.77.
Analysts are recommending an EPS of between -$5.33 and -$6.41 for the fiscal current year, implying an average EPS of -$5.77. EPS for the following year is -$4.47, with 12.0 analysts recommending between -$2.68 and -$6.41.
Revenue Estimates
According to 16 analysts,. The current quarter’s revenue is expected to be $188.05M. It ranges from a high estimate of $197M to a low estimate of $175.1M. As of. The current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $164.88MFor the next quarter, 16 analysts are estimating revenue of $172.08M. There is a high estimate of $197.47M for the next quarter, whereas the lowest estimate is $145M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $667.91M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $655.17M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $795.59M in the next fiscal year. The high estimate is $886.7M and the low estimate is $675.4M.
